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Edited by Ned ManteiAbstract Liver X receptors (LXRs) a and b share considerable
sequence homology and several functions, respond to the same
endogenous and synthetic ligands, and play critical roles in main-
taining lipid homeostasis. In this study, liverwort-derived riccar-
din C (RC) and F (RF) were identiﬁed as an LXRa agonist/
LXRb antagonist and an LXRa antagonist, respectively. RC
and RF bound to LXRs, but had diﬀerent abilities to recruit a
coactivator and thereby induce transactivation. Despite its un-
ique subtype-selective activity, RC enhanced ABCA1 and
ABCG1 expression and cellular cholesterol eﬄux in THP-1
cells. RC may provide a novel tool for identifying subtype-func-
tion and drug development.
 2005 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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The liver X receptors a and b (LXRa and LXRb) are nuclear
receptors that form obligate heterodimers with retinoidX recep-
tor (RXR) [1]. LXRs are activated by several oxysterols or inter-
mediates in the cholesterol synthetic pathway [2,3] and serve as
key regulators of cholesterol homeostasis by coordinately regu-
lating several genes involved in the eﬄux, transport, and excre-
tion of cholesterol. These genes include ATP-binding cassette
transporter (ABC) A1, ABCG1, and apolipoprotein E – which
mediate cellular cholesterol eﬄux; cholesterol 7a-hydroxylase
– the rate liming enzyme for the conversion of cholesterol to bile
acids in the liver; andABCG5/ABCG8–transporters involved in
cholesterol /sterol excretion from the liver and intestine [1]. LXR
activation also upregulates genes involved in fatty acid and tri-
glyceride synthesis by inducing sterol regulatory element-Abbreviations: LXR, liver X receptor; RXR, retinoid X receptor; ABC,
ATP-binding cassette transporter; SREBP-1c, sterol regulatory ele-
ment-binding protein-1c; LXRE, LXR response element; 22(R)HC,
22(R)-hydroxycholesterol; TO-1317, TO-901317
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doi:10.1016/j.febslet.2005.08.054binding protein-1c (SREBP-1c) – the master regulator of genes
involved in lipogenesis [4–6] – and fatty acid synthase expression
[7].
LXRa and LXRb share a high degree of amino acid similar-
ity (78%), have similar binding aﬃnities to physiological oxy-
sterol ligands [2,3], and have several common functions,
including the upregulation of ABCA1 and ABCG1 expression
[8,9]. However, these receptors have diﬀerent tissue distribu-
tions: while LXRb is ubiquitously expressed, the expression
of LXRa is limited to the liver, kidney, intestine, adipose tis-
sue, and macrophages [10]. In the liver, LXRa serves as an
important regulator of cholesterol catabolism. Mice lacking
LXRa has no resistance to dietary cholesterol and fail to
upregulate hepatic cholesterol 7a-hydroxylase [11,12], whereas
LXRb null mice maintain their resistance. The role of LXR
subtypes in triglyceride metabolism is uncertain. One study
has shown a reduction in the liver triglyceride level of LXRb
null mice on standard diet [13], whereas a reduction in the
expression of lipogenic genes was observed in LXRa null mice
fed cholesterol [11,12]. Thus, selective agonists for each LXR
subtype may be necessary to elucidate their precise functions.
Riccardin C (RC) and F (RF) are non-sterol natural prod-
ucts isolated from liverworts [14,15] (Fig. 1A). In the present
study, we discovered that RC functions as an LXRa-selective
agonist/LXRb antagonist but eﬀectively enhances cholesterol
eﬄux from THP-1 cells.2. Materials and methods
2.1. Riccardins C and F
RC and RF were puriﬁed from a methanol extract of the liverwort
Blasia pusilla as described previously [14,15].
2.2. Transient transfections and reporter gene assay
CV-1 cells maintained in DMEM containing 10% FCS were co-
transfected with 248 ng of LXR response element (LXRE)-driven
luciferase vector (pLXREX4-tk-Luc), 248 ng of pSV-b-galactosidase
control vector (Promega), and 1.25 ng each of pcDNA3.1-LXRa or
LXRb and pcDNA3.1-RXRa with Polyfect (Qiagen) in 24-well plates
according to a previously described method [16]. Three hours after
transfection, the cells were treated with test compounds in DMEM
containing 10% delipidated FBS, 20 lM compactin, and 10 lM meva-
lonic acid for 24 h. The cells were then lysed and the reporter gene
activity was determined. Luciferase activity was normalized to that
of b-galactosidase for each well.ation of European Biochemical Societies.
Fig. 1. RC activates LXRa but not LXRb. (A) Chemical structures of RC and RF. (B) CV-1 cells were transfected with a reporter plasmid
(pLXREX4-tk-Luc) and expression plasmids for LXRa (or LXRb) and RXRa, together with a b-galactosidase as an internal control, and were
treated for 24 h with various concentrations of RC, RF, or 22(R)HC. Luciferase activity in the cell extracts was normalized using b-galactosidase and
expressed as the fold induction relative to vehicle-treated cells. The values are the means ± S.D. of six experiments. (C) Eﬀects of RC and RF on
transcriptional activities of heterodimers between RXRa and RARa, RARb, RARc, FXR, LXRa, or LXRb, and RXRa homodimers. CV-1 cells
were transfected with expression plasmids for receptors and a b-galactosidase together with a reporter plasmid (pDR5X3-cmv-Luc for RARs,
pFXREX4-tk-Luc, or pDR1X4-cmv-Luc for RXRa), or a PPARc-Gal4-expression plasmid with a pGal4-UAS-Luc. The cells were exposed to RC
(30 lM), RF (30 lM), or receptor-speciﬁc agonists (3 lM all-trans retinoic acid for RARs and RXRa, 30 lM chenodeoxycholic acid for FXR,
20 lM 22(R)HC for LXRs, 30 lM ciglitazone for PPARc) for 24 h before assaying luciferase activity. The values are the means ± S.D. (n = 3). (D)
Puriﬁed GST-LXRa or GST-LXRb ligand binding domain was incubated with a ﬂuorescence-tagged SRC-1 peptide and various concentrations of
RC, RF, or 22(R)HC. The association of ligand-induced SRC-1 peptide with the receptor was monitored by evaluating the increases in
millipolarization ﬂuorescence units (mP). The values are the means ± S.D. of six experiments.
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A coactivator association assay using ﬂuorescence polarization
was performed according to a previously described method [16]. A
TAMRA-labeled peptide (0.1 lM with the amino acid sequence
ILRKLLQE) was incubated with puriﬁed 1.5 lM GST-fused human
LXRa ligand binding domain or LXRb ligand binding domain in100 ll of buﬀer (10 mM HEPES, 150 mM NaCl, 2 mM MgCl2, and
5 mM DTT at pH 7.9) in 96-well black polypropylene plates. After
1-h incubation at room temperature, ligand-dependent recruitment
of the coactivator-peptide was measured as the increase in ﬂuorescence
polarization using a Fluorescence Plate Reader Fusiona (Perkin–
Elmer Life Science).
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Gene-speciﬁc mRNA quantitation was performed by real-time
RT-PCR on an ABI Prism 7700 sequence detection system (Ap-
plied Biosystems). THP-1 cells maintained in RPMI 1640 medium
(Sigma) containing 10% FCS were subcultured in 6-well plates and
treated with test compounds in RPMI 1640 containing 0.2% bo-
vine serum albumin. Total RNA extracted from cells using an
RNeasy Kit (Qiagen) was treated with DNase according to the
manufacturers instructions. The relative mRNA expression levels
were determined using the TaqMan one-step RT-PCR Master
Mix (PE Applied Biosystems). The primer/probe sequences for
human ABCA1, ABCG1, and SREBP-1c have been previously
reported [17].2.5. Measurement of lipid eﬄux to apolipoprotein A-I
The lipid eﬄux measurements were performed according to a previ-
ously described method [18]. Brieﬂy, THP-1 cells were treated with the
test compounds and 0 or 10 lg/ml of human apoA-I, isolated from the
plasma HDL fraction, in RPMI 1640 containing 0.2% bovine serum
albumin for 24 h. The lipids were extracted and the cholesterol level
was determined using enzymatic methods.2.6. Statistical analysis
Data were analyzed by ANOVA followed by the Student–Newman–
Keuls method.Fig. 2. RC competes with endogenous or synthetic ligands for LXR activati
LXRa, GST-LXRb, or GST. The changes in ﬂuorescence polarization cause
RC or RF are shown. A blank value in the absence of ligands was subtracted
CV-1 cells were transfected with pLXREx4-tk-Luc and either LXRa/RXRa or
various concentrations of TO-1317 with or without RC or RF (10 or 30 lM
triplicate. Data were normalized to no ligand control (take as 1) and 100 nM
from respective controls (\, P < 0.05). (C) HepG2 cells were transfected wit
(10 nM) with or without compactin (50 lM) and mevalonic acid (40 lM).
triplicate. Signiﬁcantly diﬀerent from respective controls (\, P < 0.05). (D)
(DMSO) alone, RC or RF (30 lM) in the presence or absence of 100 nM TO
real-time PCR. Data were normalized to 18S rRNA levels and are expressed
values are the means ± S.D. (n = 3). Signiﬁcantly diﬀerent from vehicle cont3. Results
3.1. Identiﬁcation of RC as an LXRa Agonist
To discover novel LXR agonists, we screened a variety of
natural products using a transient transfection assay. CV-1
cells were cotransfected with an LXRE-driven luciferase repor-
ter plasmid and expression plasmids for human LXRa (or
LXRb) and RXRa. RC and RF (Fig. 1A) are novel macrocy-
clic bis(bibenzyl) dimers isolated from the liverwort [14,15].
Upon cotransfection with LXRa/RXR, RC (30 lM) raised
the transactivation of the reporter gene by approximately 15-
fold, while a natural LXR agonist, 22(R)-hydroxycholesterol
(22(R)HC), resulted in a 30-fold increase (Fig. 1B). At higher
concentrations, RC caused a decrease in b-galactosidase activ-
ity. LXRb/RXRa-dependent transactivation was unaﬀected by
this compound. RF, a 14-methoxyl derivative of RC, activated
neither LXRa nor LXRb. Furthermore, neither RC nor RF
activated heterodimers between RXRa and RARa, RARb,
RARc, FXR, or PPARc, and RXRa homodimers in cell-
based luciferase assays (Fig. 1C).
In an in vitro coactivator-recruitment assay, RC (up to
10 lM) induced a dose-dependent interaction between SRC-1on. (A) Fluorescence-tagged SRC-1 peptide was incubated with GST-
d by 1 lM TO-1317 in the presence of the indicated concentrations of
from the measured values. The values are the means ± S.D. (n = 3). (B)
LXRb/RXRa plasmids, as shown in Fig. 1B, and treated for 24 h with
). The values are the means ± S.D. of three experiments performed in
TO-1317 values of a representative experiment. Signiﬁcantly diﬀerent
h pLXRE-tk-Luc and treated for 24 h with RC (30 lM) or TO-1317
The values are the means ± S.D. of three experiments performed in
THP-1 cells and HepG2 cells were treated for 24 h with the vehicle
-1317. SREBP-1c mRNA level was measured by TaqMan quantitative
as the fold induction relative to that in the vehicle-treated cells. The
rols (\, P < 0.05) or cells treated with TO-1317 alone (, P < 0.05).
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trations, RC caused non-speciﬁc interference in monitoring
ﬂuorescence polarization. No interactions were induced by RF.
3.2. RC and RF compete with synthetic or endogenous ligands
for LXR activation
When assayed in the presence of 1 lM TO-1317 (TO-
901317), RC and RF reduced the TO-1317-induced association
of the SRC-1 peptide with LXRa or LXRb, indicating the
binding of these compounds to the receptors (Fig. 2A). These
compounds also decreased LXRa-transactivation elicited by a
synthetic LXR agonist TO-1317 (Fig. 2B), although inhibitory
eﬀect of RF on LXRb was insigniﬁcant. The ability of RC and
RF to compete with endogenous ligands was tested in HepG2
cells. Treatment of the cells with compactin, which has been re-
ported to deplete endogenous ligands for LXR [19,20], led to a
60% reduction in LXRE-dependent transactivation (Fig. 2C).
Similarly, RF decreased the luciferase activity to the level of
cells treated with compactin. RC had no eﬀect in the absence
of compactin but increased luciferase activity by 1.6-fold in
compactin-treated cells. RC and RF inhibited the TO-1317-
elicited expression of SREBP-1c mRNA in THP-1 cells. RF
also decreased the TO-1317-elicited expression in HepG2 cells,
although the eﬀect of RC was insigniﬁcant (Fig. 2D).Fig. 3. RC increases ABCA1 and ABCG1 mRNA expression and cellular ch
HepG2 cells. (A) THP-1 cells were treated for 24 h with the vehicle (DMSO) a
of ABCA1 and ABCG1 mRNA were measured with TaqMan quantitative re
and are expressed as the fold induction relative to that in the vehicle-treated c
triplicate. (B) Cells were treated for 24 h with the indicated compounds in the
into the medium was analyzed. The values are the means ± S.D. (n = 3) of
treated for 24 h with the vehicle (DMSO) alone, RC (30 lM), or TO-1317 (1
quantitative real-time PCR. Data were normalized to 18S rRNA levels and a
cells. The values are the means ± S.D. of three experiments. Statistically signi
NS, not signiﬁcant).3.3. RC enhances ApoA-I-mediated cellular cholesterol release
We used real-time quantitative PCR to investigate the eﬀect
of RC on the expression of LXR target genes, ABCA1,
ABCG1, and SREBP-1c, in THP-1 cells. RC (30 lM) in-
creased the ABCA1 mRNA level by 2-fold, while 22RHC
(12.5 lM) and TO-1317 (10 nM) caused 2.2- and 2.7-fold
inductions, respectively (Fig. 3A). Likewise, RC raised the
ABCG1 and SREBP-1c mRNA level by 2.6-fold and 1.6-fold,
respectively.
To evaluate whether the increase in ABCA1 mRNA expres-
sion was functionally relevant, we examined the eﬀect of RC
on cholesterol eﬄux from THP-1 cells. As shown in Fig. 3B,
apoA-I-dependent cholesterol release was increased 2-fold by
10 lM of RC. At 30 lM, this compound also caused a 2-fold
elevation in cholesterol release without exogenous apoA-I.
RC had no eﬀect on SREBP-1c and ABCG1 mRNA expres-
sion in HepG2 cells, whereas TO-1317 markedly induced
expression of both of them (Fig. 3C).4. Discussion
In the present study, we identiﬁed RC as an LXRa-selective
agonist. RC bound directly to LXRa and recruited the coacti-olesterol eﬄux in THP-1 cells without raising SREBP-1c expression in
lone, RC (30 lM), TO-1317 (10 nM), or 22(R)HC (12.5 lM). The levels
al-time PCR analysis. Data were normalized using the 18S rRNA levels
ells. The values are the means ± S.D. of three experiments performed in
presence or absence of apoA-I (10 lg/ml), and the cholesterol released
a typical series of three experiments performed. (C) HepG2 cells were
0 nM or 1 lM). SREBP-1c and ABCG1 mRNA level was measured by
re expressed as the fold induction relative to that in the vehicle-treated
ﬁcant diﬀerences from control are indicated by asterisk (\, P < 0.05 and
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activation of LXRa-dependent reporter gene transcription
(Fig. 1B). RC also possesses the ability to bind to LXRb. How-
ever, its inability to recruit a coactivator to LXRb (Fig. 1D)
resulted in the failure of LXRb-mediated transactivation. RC
was shown to have no ability to activate PPARc, RARa,
RARb, RARc, FXR, and RXRa (Fig. 1C).
In contrast to RC, RF was inactive for both LXRa and
LXRb-mediated transactivation (Fig. 1B). This compound
was able to bind to LXRa and LXRb (Fig. 2A) but was unable
to promote coactivator association (Fig. 1C). Structural diﬀer-
ences between RC and RF suggest that the C-14 hydroxyl
group of RC plays a critical role in inducing coactivator asso-
ciation to LXRa, but not to LXRb, leading to transactivation
in a subtype-selective manner.
The competition with the synthetic agonist TO-1317 for the
coactivator association (Fig. 2A) and the receptor-mediated
transactivation (Fig. 2B) demonstrates that RC functions as
an LXRa partial agonist and an LXRb antagonist. RF func-
tions as an antagonist of LXRa. RF decreased LXRE-depen-
dent luciferase transcription in HepG2 cells to the level of
endogenous-ligand depletion by compactin (Fig. 2C), suggest-
ing that endogenous ligand-mediated LXR activation was
inhibited by RF. RC increased LXRE-dependent transcription
in compactin-treated cells, but not in the absence of compactin.
In the intact cells, RC, as well as RF, might compete with
endogenous ligands for LXR activation, thereby decreasing
endogenous ligand-mediated activation. This latent activity of
RCmight compensate for this reduction. RC and RF also com-
peted with TO-1317 for SREBP-1c expression in THP-1 cells.
The eﬄux of cellular cholesterol to HDL constitutes the ﬁrst
stage in the reverse cholesterol transport pathway and plays a
critical role in modulating the progression of atherosclerosis
[21]. ABCA1 and ABCG1 have been shown to mediate this
process [22,23], and LXRa and LXRb play redundant roles
in their expression [9,24]. RC functions as an LXRa partial
agonist and LXRb antagonist. However, RC was shown to
raise ABCA1 and ABCG1 mRNA levels and enhance cellular
cholesterol eﬄux in THP-1 cells (Fig. 3A and B). Because hu-
man LXRa expression is autoregulated by LXRa itself [25],
the stimulation of LXRa may have a stronger eﬀect than that
of LXRb. RC and TO-1317 at higher concentrations increased
cholesterol eﬄux even in the absence of apoA-I. Because THP-
1 cells express apoE [26] and ABCA1 at the basal level,
increased expression of apoE by LXR activation [27], caveo-
lin-1 [28], or ABCA7 [29] could lead to enhanced cholesterol
release, even without apoA-I.
We found that RC did not aﬀect SREBP-1c and ABCG1
expression in hepatoma HepG2 cells (Fig. 3C). This coincides
with the apparent inability of RC to enhance LXRE-dependent
transactivation in this cell line (Fig. 2C). A possible explanation
for this inability is the low LXRa/LXRb ratio in HepG2 cells.
Alternatively, as a partial LXRa agonist/LXRb antagonist, RC
might compete with endogenous ligands produced via the cho-
lesterol synthesis pathway. It is also possible that coactivator-
corepressor(s) diﬀerent from those employed in THP-1 cells
might be active in this cell line. Further studies are required
to elucidate the precise mechanisms of RCs selective actions.
However, because synthetic LXR agonists have been shown
to cause hypertriglyceridemia [5], LXR modulators that do
not upregulate hepatic lipogenic genes may enable improved
therapeutic strategies.Acknowledgments: This work was supported in part by a grant (MF-
16) from the Organization for Pharmaceutical Safety and Research
and a grant from the Japan Health Sciences Foundation.
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